At the news
? MIXEDIMPACT 6/10 8-K filed Apr 14, 2026 at 08:15 ET
Harmony Biosciences announced the departure of CFO Sandip Kapadia and the immediate appointment of Glenn Reicin as his replacement. The company reiterated its 2026 net revenue guidance of $1.0–1.04 billion. This leadership transition follows a recent proxy fight, suggesting ongoing board-level tensions.
- CFO Sandip Kapadia stepped down effective April 14, 2026, after serving since 2021
- Glenn Reicin appointed as new CFO effective immediately, with a $500,000 base salary and $3 million option grant
- Kapadia's separation agreement includes $539,000 severance and accelerated vesting of October 2023 equity awards
- Company reaffirmed 2026 net revenue guidance of $1.0–1.04 billion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access